Inspiring Wholeness Podcast Explores Breakthroughs in Breast Cancer Treatment and the Role of Genomic Testing in Personalized Medicine

Side by side headshots of Dr. Lisa Minton and Dr. Wes Walker
Dr. Lisa Minton, breast cancer surgeon at AdventHealth Medical Group (left) and Dr. Wes Walker, director of genomics and personalized health at AdventHealth (right)

With an estimated 265,000 people who will be diagnosed with breast cancer in the United States this year, including men, regular screenings and self-exams will translate into improved survival rates because the cancers will likely be detected at earlier stages. That’s according to Dr. Lisa Minton, a board-certified general surgeon who specializes in breast care at AdventHealth Medical Group.

In this episode of the Inspiring Wholeness podcast, Minton and Dr. Wes Walker, director of genomics and personalized health at AdventHealth, discuss breakthroughs in breast cancer research, the role of genomic testing in personalized medicine and how patients can take preventative measures.

Listen now and subscribe so you never miss a new episode.

Recent News

12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News
AdventHealth Celebration Successfully Performs First Robotics-assisted Cochlear Implant Procedure in Florida with the iotaSOFT® Insertion System.

In January 2024, AdventHealth Celebration neurotologist Michael Seidman, MD, FACS, became the first in Florida and the Southeast to complete a robotics-assisted cochlear implant procedure using the...

Read Article about "AdventHealth Celebration Successfully Performs First Robotics-assisted Cochlear Implant Procedure in Florida with the iotaSOFT® Insertion System."
News
New England Journal of Medicine highlights Guru Sonpavde, MD’s work in new immunotherapy-chemotherapy combination improving survival for patients with advanced urothelial carcinoma

The CheckMate 901 Phase III clinical trial results, recently published in the New England Journal of Medicine, found that combining the programmed death 1 (PD1) inhibitor immunotherapy nivolumab with...

Read Article about "New England Journal of Medicine highlights Guru Sonpavde, MD’s work in new immunotherapy-chemotherapy combination improving survival for patients with advanced urothelial carcinoma"
View More Articles